Plus   Neg

Stock Alert: Heron Therapeutics Slips 30% Following FDA Letter

Shares of Heron Therapeutics, Inc. (HRTX) are falling more than 30% Monday morning after the biotechnology company announced that it received a Complete Response Letter from the FDA on June 26, 2020, regarding its New Drug Application for its drug candidate HTX-011, proposed for the management of postoperative pain.

The Complete Response Letter has requested additional non-clinical information. The FDA did not identify any clinical safety or efficacy issues or CMC issues, the company said in a statement.

Heron stock is currently trading at $13.62. It has traded in the range of $9.60- $26.81in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..." Novartis AG (NVS) agreed to pay $678 million to settle U.S. government charges it paid illegal kickbacks to doctors to induce them to prescribe its cardiovascular and diabetes drugs, the U.S. Department of Justice said in a statement. PG&E Corp. (PCG) said Wednesday that it has emerged from Chapter 11 bankruptcy protection, after implementing its financial restructuring plan that was previously approved by the U.S. Bankruptcy Court and state regulators.
Follow RTT